<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31128770</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6838</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>American journal of kidney diseases : the official journal of the National Kidney Foundation</Title><ISOAbbreviation>Am J Kidney Dis</ISOAbbreviation></Journal><ArticleTitle>Association of Serum Uromodulin With ESKD and Kidney Function Decline in the Elderly: The Cardiovascular Health Study.</ArticleTitle><Pagination><StartPage>501</StartPage><EndPage>509</EndPage><MedlinePgn>501-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.ajkd.2019.02.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0272-6386(19)30664-X</ELocationID><Abstract><AbstractText Label="RATIONALE &amp; OBJECTIVE">Uromodulin is released by tubular epithelial cells into the serum and lower levels are associated with more severe interstitial fibrosis and tubular atrophy. Low serum uromodulin (sUMOD) levels are associated with mortality and cardiovascular disease. However, little is known about the association of sUMOD levels with long-term kidney outcomes in older adults, a population with a high prevalence of interstitial fibrosis and tubular atrophy.</AbstractText><AbstractText Label="STUDY DESIGN">Case-cohort study and case-control study.</AbstractText><AbstractText Label="SETTING &amp; PARTICIPANTS">Random subcohort (n=933) and additional cases of end-stage kidney disease (ESKD) and kidney function decline (&#x2265;30% decline in estimated glomerular filtration rate [eGFR]) during follow-up of the Cardiovascular Health Study (CHS).</AbstractText><AbstractText Label="PREDICTOR">sUMOD level.</AbstractText><AbstractText Label="OUTCOMES">ESKD (n=14) from the random subcohort and all additional ESKD cases from outside the random subcohort (n=39) during follow-up (10 years, case-cohort study); kidney function decline of&#x2265;30% eGFR at 9 years of follow-up in individuals with repeated eGFR assessments from the random subcohort (n=56) and additional cases (n=123). 224 participants from the random subcohort served as controls (case-control study).</AbstractText><AbstractText Label="ANALYTICAL APPROACH">Modified multivariable Cox regression for ESKD and multivariable logistic regression for kidney function decline. Both analyses adjusted for demographics, eGFR, urinary albumin-creatinine ratio, and other kidney disease progression risk factors.</AbstractText><AbstractText Label="RESULTS">Mean age of the random subcohort was 78 years, 40% were men, 15% were black. Mean sUMOD level was 127&#xb1;64ng/mL and eGFR was 63&#xb1;19mL/min/1.73m<sup>2</sup>. In multivariable analysis, each 1-SD higher sUMOD level was associated with 63% lower risk for ESKD (HR, 0.37; 95% CI, 0.14-0.95). In demographic-adjusted analyses of kidney function decline, each 1-SD higher sUMOD level was associated with 25% lower odds of kidney function decline (OR, 0.75; 95% CI, 0.60-0.95); after multivariable adjustment, the association was attenuated and no longer significant (OR, 0.88; 95% CI, 0.68-1.14).</AbstractText><AbstractText Label="LIMITATIONS">Possibility of survival bias in the kidney function decline analysis.</AbstractText><AbstractText Label="CONCLUSIONS">Higher sUMOD levels may identify elderly persons at reduced risk for ESKD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steubl</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA; Division of Nephrology, Klinikum rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buzkova</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garimella</LastName><ForeName>Pranav S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ix</LastName><ForeName>Joachim H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devarajan</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Paolo H M</ForeName><Initials>PHM</Initials><AffiliationInfo><Affiliation>Benjamin Leon Center for Geriatric Research and Education, Herbert Wertheim College of Medicine, Florida International University, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shlipak</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnak</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. Electronic address: msarnak@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 DK007777</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK098234</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL130114</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268200800007C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK114556</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC55222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201200036C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 DK096418</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC75150</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Kidney Dis</MedlineTA><NlmUniqueID>8110075</NlmUniqueID><ISSNLinking>0272-6386</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058949">Uromodulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007677" MajorTopicYN="N">Kidney Function Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058949" MajorTopicYN="N">Uromodulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tamm-Horsfall-protein</Keyword><Keyword MajorTopicYN="N">Uromodulin</Keyword><Keyword MajorTopicYN="N">cardiovascular disease (CVD)</Keyword><Keyword MajorTopicYN="N">chronic kidney disease (CKD)</Keyword><Keyword MajorTopicYN="N">end-stage renal disease (ESRD)</Keyword><Keyword MajorTopicYN="N">estimated glomerular filtration (eGFR)</Keyword><Keyword MajorTopicYN="N">kidney function decline</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">renal end point</Keyword><Keyword MajorTopicYN="N">sUMOD</Keyword><Keyword MajorTopicYN="N">tubular function</Keyword></KeywordList><CoiStatement>Financial Disclosure: The authors declare that they have no relevant financial interests. Peer Review: Received _______. Evaluated by 2 external peer reviewers and a statistician, with direct editorial input from a Statistics/Methods Editor and an International Editor, who served as Acting Editor-in-Chief. Accepted in revised form February 28, 2019. The involvement of an Acting Editor-in-Chief was to comply with AJKD&#x2019;s procedures for potential conflicts of interest for editors, described in the Information for Authors &amp; Journal Policies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31128770</ArticleId><ArticleId IdType="mid">NIHMS1530113</ArticleId><ArticleId IdType="pmc">PMC7188359</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2019.02.024</ArticleId><ArticleId IdType="pii">S0272-6386(19)30664-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in Prevalence of Chronic Kidney Disease in the United States. Annals of internal medicine. 2016;165(7):473&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552458</ArticleId><ArticleId IdType="pubmed">27479614</ArticleId></ArticleIdList></Reference><Reference><Citation>Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney international. 2011;79(12):1331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917543</ArticleId><ArticleId IdType="pubmed">21289598</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clinical journal of the American Society of Nephrology : CJASN. 2008;3(2):348&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390952</ArticleId><ArticleId IdType="pubmed">18235143</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, et al. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol. 2017;32(1):139&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">27557557</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney international. 2014;86(4):828&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184028</ArticleId><ArticleId IdType="pubmed">24694989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum JL, Mikail M, Wiedmann F. Further correlation of renal function with kidney biopsy in chronic renal disease. The American journal of the medical sciences. 1967;254(2):156&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">4951793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T, et al. Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">29788462</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittier WL. Complications of the percutaneous kidney biopsy. Advances in chronic kidney disease. 2012;19(3):179&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">22578678</ArticleId></ArticleIdList></Reference><Reference><Citation>Devuyst O, Olinger E, Rampoldi L. Uromodulin: from physiology to rare and complex kidney disorders. Nature reviews Nephrology. 2017;13(9):525&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28781372</ArticleId></ArticleIdList></Reference><Reference><Citation>Iorember FM, Vehaskari VM. Uromodulin: old friend with new roles in health and disease. Pediatric nephrology (Berlin, Germany). 2014;29(7):1151&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23880785</ArticleId></ArticleIdList></Reference><Reference><Citation>Scolari F, Izzi C, Ghiggeri GM. Uromodulin: from monogenic to multifactorial diseases. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30(8):1250&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25228753</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, Jennings P. Evidence for a role of uromodulin in chronic kidney disease progression. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association. 2010;25(6):1896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">20075439</ArticleId></ArticleIdList></Reference><Reference><Citation>Steubl D, Block M, Herbst V, Nockher WA, Schlumberger W, Satanovskij R, et al. Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients. Medicine. 2016;95(10):e3011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4998896</ArticleId><ArticleId IdType="pubmed">26962815</ArticleId></ArticleIdList></Reference><Reference><Citation>Risch L, Lhotta K, Meier D, Medina-Escobar P, Nydegger UE, Risch M. The serum uromodulin level is associated with kidney function. Clinical chemistry and laboratory medicine. 2014;52(12):1755&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24933630</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedak D, Kuzniewski M, Fugiel A, Wieczorek-Surdacka E, Przepiorkowska-Hoyer B, Jasik P, et al. Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol Arch Med Wewn. 2016;126(12):995&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">27958261</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiherer A, Muendlein A, Saely CH, Brandtner EM, Geiger K, Fraunberger P, et al. The value of uromodulin as a new serum marker to predict decline in renal function. Journal of hypertension. 2018;36(1):110&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28858977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostom A, Steubl D, Garimella PS, Franceschini N, Roberts MB, Pasch A, et al. Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American journal of nephrology. 2018;47(4):275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754623</ArticleId><ArticleId IdType="pubmed">29698955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Annals of epidemiology. 1991;1(3):263&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1&#x2013;11.</Citation></Reference><Reference><Citation>Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. Journal of clinical epidemiology. 1999;52(12):1165&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10580779</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. Journal of general internal medicine. 2011;26(4):379&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055978</ArticleId><ArticleId IdType="pubmed">20853156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ix JH, Biggs ML, Mukamal K, Djousse L, Siscovick D, Tracy R, et al. Urine Collagen Fragments and CKD Progression-The Cardiovascular Health Study. Journal of the American Society of Nephrology : JASN. 2015;26(10):2494&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587692</ArticleId><ArticleId IdType="pubmed">25655067</ArticleId></ArticleIdList></Reference><Reference><Citation>Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24):2518&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172342</ArticleId><ArticleId IdType="pubmed">24892770</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;64(6):821&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25441437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;64(6):860&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25441439</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. The New England journal of medicine. 2012;367(1):20&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398023</ArticleId><ArticleId IdType="pubmed">22762315</ArticleId></ArticleIdList></Reference><Reference><Citation>Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clinical chemistry. 1997;43(6 Pt 1):1016&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Ying ZW. Cox regression with incomplete covariate measurements. Journal of the American Statistical Association. 1993;88 (424):1341&#x2013;9.</Citation></Reference><Reference><Citation>Borgan O, Langholz B, Samuelsen SO, Goldstein L, Pogoda J. Exposure stratified case-cohort designs. Lifetime data analysis. 2000;6(1):39&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">10763560</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggins RC. Uromucoid (Tamm-Horsfall glycoprotein) forms different polymeric arrangements on a filter surface under different physicochemical conditions. Clinica chimica acta; international journal of clinical chemistry. 1987;162(3):329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutig K, Kahl T, Saritas T, Godes M, Persson P, Bates J, et al. Activation of the bumetanide-sensitive Na+,K+,2Cl- cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. The Journal of biological chemistry. 2011;286(34):30200&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191059</ArticleId><ArticleId IdType="pubmed">21737451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann S, Mutig K, Bates J, Welker P, Geist B, Gross V, et al. Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. American journal of physiology Renal physiology. 2005;288(3):F559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522986</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini-Cessi F, Monti A, Cavallone D. N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. Glycoconjugate journal. 2005;22(7&#x2013;9):383&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16622944</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, et al. Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. American journal of physiology Renal physiology. 2010;299(3):F469&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944300</ArticleId><ArticleId IdType="pubmed">20591941</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, Holm H, Indridason OS, Thorleifsson G, Edvardsson V, Sulem P, et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS genetics. 2010;6(7):e1001039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912386</ArticleId><ArticleId IdType="pubmed">20686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Garimella PS, Katz R, Ix JH, Fried LF, Kritchevsky SB, Devarajan P, et al. Association of urinary uromodulin with kidney function decline and mortality: the health ABC study. Clinical nephrology. 2017;87(6):278&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102560</ArticleId><ArticleId IdType="pubmed">28332475</ArticleId></ArticleIdList></Reference><Reference><Citation>Garimella PS, Biggs ML, Katz R, Ix JH, Bennett MR, Devarajan P, et al. Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults. Kidney international. 2015;88(5):1126&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653069</ArticleId><ArticleId IdType="pubmed">26154925</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease Lancet; (London, England: ). 2017;389(10075):1238&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27887750</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodall AA, Marshall RD. Effects of freezing on the estimated amounts of Tamm--Horsfall glycoprotein in urine, as determined by radioimmunoassay. The Biochemical journal. 1980;189(3):533&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1162033</ArticleId><ArticleId IdType="pubmed">7213344</ArticleId></ArticleIdList></Reference><Reference><Citation>Youhanna S, Weber J, Beaujean V, Glaudemans B, Sobek J, Devuyst O. Determination of uromodulin in human urine: influence of storage and processing. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association. 2014;29(1):136&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24097801</ArticleId></ArticleIdList></Reference><Reference><Citation>Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet; (London, England: ). 1968;2(7564):363&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">4173786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol. 2009;20(5):1149&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678047</ArticleId><ArticleId IdType="pubmed">19389845</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Achkar TM, McCracken R, Liu Y, Heitmeier MR, Bourgeois S, Ryerse J, et al. Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injury. American journal of physiology Renal physiology. 2013;304(8):F1066&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625838</ArticleId><ArticleId IdType="pubmed">23389456</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. American journal of physiology Renal physiology. 2008;295(2):F534&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504389</ArticleId><ArticleId IdType="pubmed">18495803</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;64(4):534&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177290</ArticleId><ArticleId IdType="pubmed">24953891</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenstein L, Driver TH, Fried LF, Rifkin DE, Patel KV, Yenchek RH, et al. Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;64(4):542&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177317</ArticleId><ArticleId IdType="pubmed">24953890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. Journal of the American Society of Nephrology : JASN. 2009;20(1):223&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615732</ArticleId><ArticleId IdType="pubmed">19020007</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Achkar TM, McCracken R, Rauchman M, Heitmeier MR, Al-Aly Z, Dagher PC, et al. Tamm-Horsfall protein-deficient thick ascending limbs promote injury to neighboring S3 segments in an MIP-2-dependent mechanism. American journal of physiology Renal physiology. 2011;300(4):F999&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504439</ArticleId><ArticleId IdType="pubmed">21228114</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherberich JE, Gruber R, Nockher WA, Christensen EI, Schmitt H, Herbst V, et al. Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association. 2018;33(2):284&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837243</ArticleId><ArticleId IdType="pubmed">28206617</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian L, Fa X, Zhou Z, Liu S. Functional analysis of UMOD gene and its effect on inflammatory cytokines in serum of essential hypertension patients. International journal of clinical and experimental pathology. 2015;8(9):11356&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4637676</ArticleId><ArticleId IdType="pubmed">26617860</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BA, Katz R, Boulware LE, Kestenbaum B, de Boer IH, Wang W, et al. Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). American journal of kidney diseases : the official journal of the National Kidney Foundation. 2016;68(2):229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445065</ArticleId><ArticleId IdType="pubmed">27066930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Archives of internal medicine. 2009;169(4):342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727643</ArticleId><ArticleId IdType="pubmed">19237717</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado GE, Kleber ME, Scharnagl H, Kramer BK, Marz W, Scherberich JE. Serum Uromodulin and Mortality Risk in Patients Undergoing Coronary Angiography. Journal of the American Society of Nephrology : JASN. 2017;28(7):2201&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491294</ArticleId><ArticleId IdType="pubmed">28242751</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Annals of internal medicine. 2010;152(9):561&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864956</ArticleId><ArticleId IdType="pubmed">20439574</ArticleId></ArticleIdList></Reference><Reference><Citation>Putt TL, Duffull SB, Schollum JB, Walker RJ. GFR may not accurately predict aspects of proximal tubule drug handling. European journal of clinical pharmacology. 2014;70(10):1221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25135059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>